In the preclinical setting, this is well exemplified by the inactivity of EGFR-TKIs in H1650 cells or tumours (NSCLC) that harbour a Del 19 EGFR mutation and are at the same time PTEN-mutated (Sos et al. 2009). This evidence concerns the gene PTEN and neoplasm.